BERGENBIO Aktie

 

Bergen, Norway – 3 July 2025: BerGenBio ASA (OSE:BGBIO) will hold an Extraordinary General Meeting virtually on 4 August 2025 at 12:00 PM (CEST).   The notice, registration form and power of attorney are attached to this release. The notice will be sent to all registered shareholders and the notice in addition to other attachments are available on the Company's website: https://www.bergenbio.com/investors/general-meetings/   All shareholders are encouraged to exercise their shareholder rights, either through advance electronically voting through VPS Investor Services, by using...

Bergen, Norway and Oslo, Norway, June 30, 2025 /PRNewswire/ -- BerGenBio ASA the ("Company") hereby announces a fully underwritten rights issue with preferential subscription rights (the "Subscription Rights") for the Company's existing shareholders at the time of completion of the......

OSLO, Norway, June 30, 2025 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO) ("BerGenBio" or the "Company") and Oncoinvent ASA (OSE: ONCIN) ("Oncoinvent") announce that they have entered into a merger agreement (the "Agreement") to combine the two companies through a statutory merger (the......

OSLO, Norway, June 30, 2025 /PRNewswire/ -- BerGenBio ASA the ("Company") hereby announces a fully underwritten rights issue with preferential subscription rights (the "Subscription Rights") for the Company's existing shareholders at the time of completion of the proposed merger between......

Bergen, Norway and Oslo, Norway, 30 June 2025: BerGenBio ASA the ("Company") hereby announces a fully underwritten rights issue with preferential subscription rights (the "Subscription Rights") for the Company's existing shareholders at the time of completion of the proposed merger between BerGenBio Norge AS, a wholly-owned subsidiary of the Company, and Oncoinvent ASA announced in a separate announcement earlier today (the "Merger") to raise gross proceeds of approximately NOK 130 million, which pursuant to certain Underwriting Agreements (as defined below) will be fully underwritten by a...

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT. Bergen, 30 June 2025: Reference is made to the stock exchange announcement published by BerGenBio ASA (the "Company") earlier today,...

Bergen, 26 June 2025: BerGenBio ASA held its annual general meeting today digitally through Lumi AGM. All resolutions were made in accordance with the proposals from the board of directors and the nomination committee, including, but not limited to, approval of the 2024 annual accounts, election of a member to and the remuneration the board of directors and nomination committee. The minutes from the annual general meeting are attached hereto and will also be made available on the company's website www.bergenbio.no.   For further information, please contact: Olav Hellebø, CEO,...

Bergen, 3 June 2025 – Reference is made to previous stock exchange announcements from BerGenBio ASA ("BerGenBio" or the "Company") dated 25 February 2025 and 17 March 2025 regarding the Company's ongoing strategic review process. Strategic review process is ongoing With reference to the announcement 17 March 2025, engaging DNB Carnegie as financial advisor for the strategic review process, the process remains ongoing. As previously communicated, the Board of Directors will, as part of this process, consider a range of options for the Company, including, among other things, a potential...

Bergen, Norway – 3 June 2025: BerGenBio ASA (OSE:BGBIO) will be holding its Annual General Meeting virtually on 26 June 2025 at 10:00 hours (CEST).   The notice, registration form and power of attorney are attached to this release. The notice will be sent to all registered shareholders and the notice in addition to other attachments are available on the Company's website: https://www.bergenbio.com/investors/general-meetings/   All shareholders are encouraged to exercise their shareholder rights, either through advance electronically voting through VPS Investor Services, by using...

Bergen, Norway – 29 April 2025 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, announces that the Board of Directors today approved the 2024 Annual Financial Statements prepared in accordance with International Financial Reporting Standards (IFRS).   The Annual Report for 2024 in pdf and European Single Electronic Format (ESEF) are attached to this release and are also available on BerGenBio ASA's website https://www.bergenbio.com/investors/reports/   Due to the ongoing strategic...

The article identifies promising survival results in relapsed/refractory AML patients warranting further study   Bergen, Norway – 26 March 2025 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, today announces the publication of a peer-reviewed article entitled “Bemcentinib as Monotherapy and in Combination with Low-Dose Cytarabine in Acute Myeloid Leukemia Patients Unfit for Intensive Chemotherapy” in the journal Nature Communications. This article is accessible here: www.nature....

Bergen, Norway, March 17, 2025 – Reference is made to the stock exchange announcement on 25 February 2025 from BerGenBio ASA (OSE: BGBIO) (the "Company"), a clinical-stage biopharmaceutical company developing the novel, selective AXL kinase inhibitor bemcentinib for serious diseases, in which the Company amongst other things announced that it will explore strategic alternatives. The Company today announced that it has engaged Carnegie AS[i], an entity within the DNB Bank ASA group, as its financial advisor to assist in the Company's review of strategic alternatives. The management and Board...

Bergen, Norway, February 26, 2025 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharma-ceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter ended December 31, 2024, and provided a business update.   Highlights, including post period:   BGBC016 1L NSCLC STK11m Study · Yesterday the company announced its decision to close its BGBC016 study of bemcentinib in combination with standard of care therapy in first line (1L) non-squamous Non-Small Cell Lung Cancer (NSCLC) patients with...

Bergen, Norway, February 25, 2025 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing the novel, selective AXL kinase inhibitor bemcentinib for serious diseases today announced its decision to close its BGBC016 study of bemcentinib in combination with standard of care therapy in first line (1L) non-squamous Non-Small Cell Lung Cancer (NSCLC) patients with a mutation in the STK11 gene (STK11m). “It is, of course, disappointing and unexpected that we are now discontinuing the study. I would like to extend my gratitude to the patients and investigators who...

BERGEN, Norway, Jan. 7, 2025 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing the novel, selective AXL kinase inhibitor bemcentinib for lung cancer announced today that the first patient has been included in a clinical trial sponsored by......

BERGEN, Norway, November 26, 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced that the Company will present at the DNB Nordic Healthcare Conference today in Oslo, Norway at 14:45-15:05 CET.   Chief Executive Officer Olav Hellebø will provide a business update including progress of the ongoing BGBC016 clinical study in 1st line Non-Small Cell Lung Cancer patients with STK11 mutations.   The presentation used at the conference will be available in the investor...

BERGEN, Norway, Nov. 20, 2024 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today the appointment of Olav Hellebø as CEO. Mr. Hellebø will assume the......

BERGEN, Norway, Nov. 13, 2024 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharma-ceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter and half year ended September 30, 2024,......

Bergen, Norway, 5 November 2024 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, will be announcing its results for the third quarter 2024 on Wednesday 13 November 2024. BerGenBio's senior management team will provide a business update at 10:00 am CET. The presentation will webcast live. To participate in the webcast please use this link:   Webcast Q3 2024 (https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fchannel.royalcast.com%2Flandingpage%2Fhegnarmedia%2F20241113_3%...